Page 5 - புதுமையானது புதியது பரிசோதனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The study yielded sensitivity specifications of 96.2-100% and specificity specifications of 98.7-99.5% Genedrive PLC (LON:GDR) has announced the publication of a large independent multi-centre study evaluating the real-world performance of its HCV test in low and middle-income countries. The study yielded sensitivity specifications of 96.2-100% and specificity specifications of 98.7-99.5%, depending on the site or viral load, meaning the HCV -ID Kit is effective as intended in the diagnosis of HCV infection in resource-limited settings. The authors highlighted a test fail rate of 1.6%, which the AIM-listed firm said shows that the system performs to this high standard even though the system operators in the study had no previous experience in molecular testing.  

United statesDavid buddFoundation for innovative new diagnosticsAbbott realtimeInnovative new diagnosticsSmall capsHarma biotechGenedrive plcLon gdrஒன்றுபட்டது மாநிலங்களில்டேவிட் மொட்டுஅடித்தளம் க்கு புதுமையானது புதியது பரிசோதனைஅப்போட் றேஆழ்டிமேபுதுமையானது புதியது பரிசோதனைசிறிய தொப்பிகள்